Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial

Amyotrophic Lateral Sclerosis (ALS) is a devastating incurable disease. Stem-cell-based therapies represent a new possible strategy for ALS clinical research. The objectives of this Phase 1 clinical study were to assess the feasibility and toxicity of mesenchymal stem cell transplantation and to test the impact of a cell therapy in ALS patients. The trial was approved and monitored by the National Institute of Health and by the Ethics Committees of all participating Institutions. Autologous MSCs were isolated from bone marrow, expanded in vitro and analyzed according to GMP conditions. Expanded MSCs were suspended in the autologous cerebrospinal fluid (CSF) and directly transplanted into the spinal cord at a high thoracic level with a surgical procedure. Ten ALS patients were enrolled and regularly monitored before and after transplantation by clinical, psychological, neuroradiological and neurophysiological assessments. There was no immediate or delayed transplant-related toxicity. Clinical, laboratory, and radiographic evaluations of the patients showed no serious transplant-related adverse events. Magnetic resonance images (MRI) showed no structural changes (including tumor formation) in either the brain or the spinal cord. However the lack of post mortem material prevents any definitive conclusion about the vitality of the MSCs after transplantation. In conclusion, this study confirms that MSC transplantation into the spinal cord of ALS patients is safe and that MSCs might have a clinical use for future ALS cell based clinical trials.

[1]  M. Cudkowicz,et al.  Is it too soon for Mesenchymal Stem Cell trials in people with ALS? , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[2]  F. Frassoni,et al.  Bone marrow harvest for marrow transplantation: effect of multiple small (2 ml) or large (20 ml) aspirates. , 1992, Bone marrow transplantation.

[3]  S. Gronthos,et al.  Mesenchymal Stem Cell‐Organized Bone Marrow Elements: An Alternative Hematopoietic Progenitor Resource , 2006, Stem cells.

[4]  H. Deda,et al.  Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. , 2009, Cytotherapy.

[5]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[6]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[7]  A. Uccelli,et al.  Mesenchymal stem cells: a new strategy for immunosuppression? , 2007, Trends in immunology.

[8]  S. Salani,et al.  Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. , 2007, Brain : a journal of neurology.

[9]  E. Beghi,et al.  The epidemiology of ALS and the role of population-based registries. , 2006, Biochimica et biophysica acta.

[10]  J. Rothstein,et al.  Focal Transplantation-based Astrocyte Replacement is Neuroprotective in a Model of Motor Neuron Disease , 2008, Nature Neuroscience.

[11]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[12]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[13]  James R. Goldenring,et al.  Gastric Cancer Originating from Bone Marrow-Derived Cells , 2004, Science.

[14]  M. Kay,et al.  Sarcoma Derived from Cultured Mesenchymal Stem Cells , 2007, Stem cells.

[15]  L. Mazzini,et al.  Bone Marrow Mesenchymal Stem Cells from Healthy Donors and Sporadic Amyotrophic Lateral Sclerosis Patients , 2008, Cell transplantation.

[16]  P. Sanberg,et al.  Positive Effect of Transplantation of hNT Neurons (NTera 2/D1 Cell-Line) in a Model of Familial Amyotrophic Lateral Sclerosis , 2002, Experimental Neurology.

[17]  D. Gutmann,et al.  Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis , 2008, Nature Neuroscience.

[18]  C. Svendsen,et al.  Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis , 2008, Trends in Neurosciences.

[19]  A. Cometa,et al.  Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms , 2010 .

[20]  L. Mazzini,et al.  Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[21]  A. Vercelli,et al.  Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis , 2008, Neurobiology of Disease.

[22]  K. Baker,et al.  Targeted Spinal Cord Therapeutics Delivery: Stabilized Platform and Microelectrode Recording Guidance Validation , 2007, Stereotactic and Functional Neurosurgery.

[23]  A. Vercelli,et al.  Mesenchymal stem cells for ALS patients , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[24]  G. Kollias,et al.  Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia , 2006, Science.

[25]  T. Siddique,et al.  Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue , 2004, Annals of neurology.

[26]  L. Mazzini,et al.  Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis , 2006, Neurological research.

[27]  D. Schoenfeld,et al.  The use of statistical MUNE in a multicenter clinical trial , 2004, Muscle & nerve.

[28]  P. Bickford,et al.  Novel cell therapy approaches for brain repair. , 2006, Progress in brain research.

[29]  P. Sanberg,et al.  Intraspinal implantation of hNT neurons into SOD1 mice with apparent motor deficit , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[30]  Jeffrey Rosenfeld,et al.  Sertoli cells improve survival of motor neurons in SOD1 transgenic mice, a model of amyotrophic lateral sclerosis , 2005, Experimental Neurology.

[31]  D J Prockop,et al.  Donor variation in the growth properties and osteogenic potential of human marrow stromal cells , 1999, Journal of cellular biochemistry.

[32]  L. Rubin,et al.  Recovery from paralysis in adult rats using embryonic stem cells , 2006, Annals of neurology.

[33]  M. Swash,et al.  Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis , 2003, Muscle & nerve.

[34]  J. Langston,et al.  Stem cells for Parkinson disease and ALS: replacement or protection? , 2004, Nature Medicine.

[35]  L. Xiang,et al.  Mesenchymal stem cells: a promising candidate in regenerative medicine. , 2008, The international journal of biochemistry & cell biology.

[36]  K. Houkin,et al.  Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia. , 2006, Brain : a journal of neurology.

[37]  J. Cigudosa,et al.  Spontaneous human adult stem cell transformation. , 2005, Cancer research.

[38]  L. Mazzini,et al.  Stem cell treatment in Amyotrophic Lateral Sclerosis , 2008, Journal of the Neurological Sciences.

[39]  Orla Hardiman,et al.  Assessing individual quality of life in amyotrophic lateral sclerosis , 2004, Quality of Life Research.

[40]  C. Donadoni,et al.  Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. , 2004, Brain : a journal of neurology.